

Index

A

- Abscess
 - epidural, 245–246
 - intracerebral, 37, 152–153, 246
 - intracranial, 219–220, 244–246
 - orbital, 153, 218–219
 - subdural, 219, 246
 - subperiosteal, 217, 218, 242–243, 244, 247, 248
- Acinar cell carcinoma, 162
- Acquired immunodeficiency syndrome (AIDS), 9, 23, 231
- Acupuncture, 133–134, 137, 138
- Acute bacterial rhinosinusitis
 - allergic rhinitis as risk factor for, 32
 - complications of, 152–153
 - definition of, 18, 65
 - diagnosis of, 18, 69
 - inflammation markers in, 33
 - differentiated from viral rhinosinusitis, 32, 70
 - microbiology of, 18–20, 30
 - pathophysiology of, 30–31
 - prevalence of, 4
 - spontaneous resolution of, 70
 - symptoms of, 209–210
 - treatment of
 - medical management, 19–20, 65–74
 - sinonasal culture-directed, 33
 - viral infections as risk factor for, 17, 18, 66, 69
- Acute rhinosinusitis, 29–38
 - average annual episodes of, 96
 - complicated, 37
 - definition of, 29–30
 - diagnosis of
 - in children, 209–211
 - diagnostic criteria for, 29–30, 31–38
 - imaging-based, 34–37, 150
 - microbiology of, 4–5
 - recurrent, 21, 22
 - in children, 216
 - eosinophil content in, 115
 - relationship to chronic rhinosinusitis, 69–70
 - signs and symptoms of, 30, 31–33
 - treatment of, 120–128, 129, 136
 - See also* Acute bacterial rhinosinusitis; Viral rhinosinusitis
- Adenocarcinoma, 162, 177
- Adenoid cystic carcinoma, 162, 178
- Adenoidectomy, 216, 260–261
- Adenoid facies, 253
- Adenoid hypertrophy, 253
 - differentiated from rhinosinusitis, 208
 - as nasal obstruction and inflammation cause, 48, 252
 - treatment of, 215, 260–261
- Adenovirus, 30, 66
- Adolescents
 - allergic rhinitis in, 108
 - frontal sinus development in, 145
 - rhinosinusitis in
 - complications of, 37, 205, 219
 - differential diagnosis of, 208
- Agger nasi cells, 146
- Airflow, nasal, 252
- Air pollution, as rhinosinusitis risk factor, 4, 8, 96
- Airways hyperresponsiveness, 188–189
- Albuterol, 196
- Allergic fungal rhinosinusitis, *see* Fungal rhinosinusitis/sinusitis, allergic
- Allergic response, as type I hypersensitivity reaction, 110
- Allergic rhinitis, 6–7, 107–108
 - as acute bacterial rhinosinusitis risk factor, 32

- Allergic rhinitis (*cont.*)
- airways hyperresponsiveness associated with, 188–189
 - asthma associated with, 111, 187, 188–190
 - histopathologic relationship, 189
 - physiological relationship, 188–189
 - temporal association, 188
 - therapeutic association, 189–190
 - in children, 208
 - chronic rhinosinusitis associated with, 86–87
 - definition of, 109, 110
 - diagnosis of, 112–118
 - allergy testing in, 114–118
 - patient history in, 112–113
 - physical examination in, 113–114
 - differentiated from rhinosinusitis, 208
 - effect on quality of life, 251
 - histopathology of, 189
 - nonnasal symptoms of, 111
 - perennial, 111, 112, 113
 - prevalence of, 188
 - rhinosinusitis associated with, 111, 118–119
 - treatment of, 120–128, 129
 - seasonal, 111–112, 113
 - symptoms of, 113
 - treatment of
 - with complementary and alternative medicine, 135–136, 139–140
 - cost of, 108
 - effect on asthma symptoms, 189–190
 - with pharmacotherapy, 121–127
 - as type I hypersensitivity reaction, 110
- Allergic rhinitis and its impact on asthma (ARIA), 112
- “Allergic shiners,” 113, 253
- Allergic symptoms
- of acute rhinosinusitis, 32
 - of chronic rhinosinusitis-related, 43
- Allergy
- definition of, 191
 - homeopathic treatment of, 137–138
 - pathophysiology of, 108–111
 - to penicillin, 71, 175
 - relationship to chronic rhinosinusitis, 55, 118–119
 - See also* Allergic rhinitis; Fungal rhinosinusitis/sinusitis, allergic
- Allergy testing
- for allergic rhinitis evaluation, 114–118
 - confirmatory tests, 115–118
 - screening tests, 114–115
 - in children, 216
 - preoperative, 252–253
- Alternaria*, 6, 81, 224–225
- American Academy of Otolaryngology–Head and Neck Surgery (AAO–HNS) Committee on Alternative Medicine, 133
- Task Force for Rhinosinusitis, 1, 2, 46
- American Academy of Pediatrics, 211
- American College of Rheumatology, 169
- Aminoglycosides, toxicity of, 79, 80
- Amoxicillin, 66, 68, 71, 77
 - use in children, 213–214
- Amphotericin, fungal resistance to, 174
- Amphotericin B, 81, 234, 235
- Anaphylaxis, 110
- Angiofibromas, 208
- Angiotensin-converting enzyme (ACE), as sarcoidosis marker, 168
- Anosmia, 43, 52, 55, 97, 167
- Antibiotic therapy
- for acute bacterial rhinosinusitis, 19–20, 26, 67, 69–72
 - failure of, 71–72
 - for acute rhinosinusitis, 5
 - in children, 213–215
 - prevalence of use of, 31
 - bacterial resistance to, 5, 31, 170, 215
 - for chronic rhinosinusitis, 76–80, 88
 - in children, failure of, 215
 - intravenous administration of, 78, 80, 84
 - for intracranial infections, 219
 - nebulized, 79
 - post-sinus surgery administration of, 103
 - for rhinosinusitis
 - cost of, 11
 - in cystic fibrosis patients, 168, 171
 - as overtreatment, 11
 - for subacute rhinosinusitis, 19–20
 - See also names of specific antibiotics*
- Antiinflammatory therapy
- for acute bacterial rhinosinusitis, 66–67
 - for chronic rhinosinusitis, 66
- Antifungal therapy, 11, 174
 - for allergic fungal sinusitis, 228
 - for chronic invasive rhinosinusitis, 24
 - for chronic rhinosinusitis, 6, 80–81
 - for invasive fungal sinusitis, 233–234
- Antigen-presenting cells, 110
- Antihistamines
- as acute bacterial rhinosinusitis treatment, 68, 72
 - as allergic rhinitis treatment, 122–123

- as chronic rhinosinusitis treatment, 86–87
 - use in children, 215
 - Antileukotriene therapy
 - for allergic rhinitis, 122, 126
 - for chronic rhinosinusitis, 86
 - for Samter's triad, 194–196
 - Antineutrophil cytoplasmic antibodies, 166, 170
 - Antinuclear antibodies, 171
 - Antrostomy, 148
 - Apert's syndrome, 209
 - Arachidonic acid, in Samter's triad, 191–193, 195
 - Arteriovenous malformations, hereditary hemorrhagic telangiectasia-related, 179–180
 - Aspergillus, 23–24, 174, 225
 - in AIDS patients, 10
 - allergic bronchopulmonary, 225, 228–229
 - in children, 217
 - hypersensitivity reactions to, 225
 - treatment of, 229
 - Aspirin
 - contraindication in Samter's triad patients, 194
 - preoperative termination of, 100–101
 - Aspirin desensitization, as Samter's triad treatment, 196–197, 200
 - Aspirin-exacerbated respiratory disease (AERD), *see* Samter's triad
 - Aspirin sensitivity triad, *see* Samter's triad
 - Astemizole, 122–123
 - Asthma
 - airways hyperresponsiveness associated with, 188–189
 - allergic rhinitis associated with, 111, 114, 187, 188–190
 - histopathologic relationship, 189
 - physiological relationship, 188–189
 - temporal association, 188
 - therapeutic association, 189–190
 - aspirin sensitivity associated with, *see* Samter's triad
 - chronic rhinosinusitis associated with, 44, 55, 97
 - diagnosis of, 53
 - effect of functional endoscopic sinus surgery on, 97
 - histopathology of, 189
 - nasal polyps associated with, 45
 - prevalence of, 188
 - rhinosinusitis associated with, 7–8, 251
 - in children, 210
 - in sinus surgery patients, 100
 - treatment of, 126
 - as type I hypersensitivity reaction, 110
 - Atopy, 6–7
 - in allergic fungal rhinosinusitis, 24, 172
 - in allergic rhinitis, 253
 - in asthma, 188
 - definition of, 108–109
 - herbal therapy and, 136
 - in rhinosinusitis, 119
 - Autoimmune disorders, as chronic rhinosinusitis cause, 165–172
 - Churg–Strauss syndrome, 169–170
 - cystic fibrosis, 168–170
 - lupus, 171–172
 - relapsing polychondritis, 170–171
 - sarcoidosis, 167–168
 - Wegener's granulomatosis, 165–167, 177
 - Azithromycin, 67
- B**
- Bacterial infections
 - as chronic rhinosinusitis risk factor, 96
 - computed tomography evaluation of, 98
 - See also specific bacteria*
 - Balloon sinuplasty, 258–259
 - Beclomethasone dipropionate, 125–126, 189, 190, 215
 - Betamethasone, contraindication in pediatric patients, 215
 - Biofilms, bacterial, 20–21, 78–79
 - Bipolaris*, 6, 24, 224–225
 - Bi Yuan Shu, 134, 135
 - B lymphocytes, 109
 - in allergic response, 110
 - Bone marrow transplant recipients, rhinosinusitis in, 10
 - Bradykinin, 31
 - Bromelain, 134, 135
 - Bronchitis, 210, 216, 217
 - Bronchospasm, 55
 - Budesonide, 125–126, 215
 - Butterbur, 134, 136
- C**
- Cacosmia, 53, 54
 - Candida*, as chronic rhinosinusitis cause, 6
 - Carotid arteries, 147
 - Caspofungin, 234–235, 236
 - Cat dander, as allergic rhinitis trigger, 120, 121
 - CD4+ T helper cells, 25–26
 - Cefpodoxime proxetil, 214
 - Ceftazidime, 80

- Cellulitis
 periorbital, 152–153, 217, 241, 242–243
 preseptal, 242
- Cephalosporins, use in children, 213, 214
- Cerebrospinal fluid leaks, 50
 functional endoscopic sinus surgery-related, 101, 105, 152, 153
 imaging of, 156, 158
- Cetirizine, 122–123
- Charcot–Leyden crystals, 226, 228
- Children
 acute bacterial rhinosinusitis in, 4, 5, 19
 causal organisms of, 70
 diagnosis of, 209–211
 treatment of, 69
 acute rhinosinusitis in, 96
 risk factors for, 208–209
 treatment of, 213–217
 adenoidectomy in, 216, 260–261
 allergic rhinitis in, 107
 chronic or recurrent rhinosinusitis in, 212–213, 216
 risk factors for, 208–209
 treatment failure in, 215–216
 treatment of, 215–216
 foreign body impaction in, 19
 fungal infections in, 217
 laryngopharyngeal reflux in, 10
 paranasal sinus development in, 205, 206
 rhinosinusitis in
 complications of, 205, 239, 244–248
 differential diagnosis of, 208
 embryonic and anatomic considerations in, 205–206
 imaging studies of, 210–211
 management of, 216–217
 microbiology of, 212–213
 physiological considerations in, 206–207
 treatment failure in, 215–216
 upper respiratory tract infections in, 207
See also Adolescents
- Chinese herbal medicine, 134, 135–136
- Chiropractic manipulation, 133–134
- Chlorpheniramine, 122
- Choanal atresia/stenosis, differentiated from rhinosinusitis, 208
- Chondroid lesions, 158–159
- Chondromas, 158–159
- Chronic rhinosinusitis
 acute exacerbation of, 21–22
 in children, 216
 conditions associated with, 75
 definition of, 20, 29–30, 41–42, 45–46, 65, 88
 development from acute rhinosinusitis, 6, 69–70
 diagnosis of, 20, 41–64, 60–62
 anterior rhinoscopy-based, 58
 computed tomography-based, 58–59
 nasal endoscopy-based, 56–58
 patient history in, 55–56
 primary investigations in, 56–59
 secondary investigations in, 60
 X-rays-based, 59
 differential diagnosis of, 43, 47–53
 fungal, 6, 10, 80–81, 96, 172–174, 177
 general host factors in, 96
 imaging of, 150–151
 as inflammatory disorder, 69
 local host factors in, 96
 microbiology of, 6, 20–21, 76, 78–79
 in children, 212–213
 as multifactorial disease, 42–43
 with nasal polyps, 75
 fungal infection-related, 80–81
 treatment of, 84, 86
 pathophysiology of, 75
 phenotypic characterization of, 75–76
 prevalence and incidence of, 41
 quality-of-life effects of, 41
 recurrent, 212–213
 relationship to acute rhinosinusitis, 6, 65, 69–70
 relationship to allergy, 55, 118–119
 relationship to asthma, 7, 188–189
 signs and symptoms of, 43–44
 duration of, 44, 45–46
 local symptoms, 43
 presenting symptoms, 47–52
 regional and systemic symptoms, 44
 relationship with computed tomography findings, 37–38
 systemic disease-related, 165–186
 autoimmune disorders, 165–172
 hematologic-oncologic illnesses, 177–183
 infectious diseases, 172–177
 treatment of, 65
 antibiotic therapy, 20, 21, 26, 76–80, 88, 253
 antifungal therapy, 80–81
 complementary and alternative medicine, 135, 137, 139–140
 immunomodulatory therapy, 81–89
 saline nasal irrigation, 139

- surgical treatment, 11, 252–253
 - without nasal polyps, 75
 - Chronic Sinusitis Survey (CSS), 12
 - Churg–Strauss syndrome, 169–170
 - Cilia, role in sphenoid sinus drainage, 146
 - Ciliary dyskinesia, 8, 32, 75, 96, 207, 217
 - Cineole, 136
 - Clarithromycin, 67
 - Clavulanate, 77
 - use in children, 214
 - Clindamycin, 215
 - Coblation, 256, 257
 - Cocaine abuse, 46, 55, 182–183
 - Common cold, *see* Viral rhinosinusitis
 - Complementary and alternative medicine (CAM), in rhinology, 133–140
 - acupuncture, 133–134, 137, 138
 - chiropractic manipulation, 133–134
 - definition of, 133
 - herbal medicines, 133, 134–136, 137
 - homeopathy, 133–134, 137–138
 - humming, 140
 - massage, 133–134, 139
 - mind–body medicine, 133
 - nasal irrigation, 139
 - phototherapy, 140
 - Urtica dioica*, 139
 - vitamin C, 139
 - Computed tomography, 148–149
 - of acute rhinosinusitis, 34, 35, 36, 37, 150
 - of chronic rhinosinusitis, 34, 36, 58–59, 150–151
 - relationship with symptoms, 37–38
 - of ethmoid sinuses, 93
 - of fungal sinusitis, 173, 230–231
 - of inflammatory disease/rhinosinusitis, 150–155
 - of neoplasms, 156, 158, 159–160
 - of pediatric rhinosinusitis, 210, 211
 - preoperative, 97–98, 252–253
 - Computed tomography cisternography, 156
 - Concha bullosa, 9, 96, 146, 207
 - Congenital lesions, imaging of, 156
 - Coronavirus, 30
 - Corticosteroid therapy
 - for acute bacterial rhinosinusitis, 66–67
 - for acute rhinosinusitis, 124
 - for allergic bronchopulmonary aspergillosis, 228–229
 - for allergic fungal sinusitis, 227–228
 - for allergic rhinitis, 122, 124–126, 125, 190
 - for chronic rhinosinusitis, 81–86, 124–126
 - for cystic fibrosis, 169
 - for nasal polyps, 260
 - postoperative administration of, 103
 - preoperative administration of, 100
 - for Samter’s triad, 194, 195, 197
 - topical intranasal, 125–126
 - Co-trimoxazole, bacterial resistance to, 5
 - Cough, 52–53
 - in children, 210
 - differential diagnosis of, 53
 - C-reactive peptide, 33
 - Cribriform plate
 - anatomy of, 240
 - endoscopic sinus surgery-related injury to, 152
 - Crouzon’s syndrome, 209
 - CT, *see* Computed tomography
 - Cultures, sinonasal, 33
 - Curvularia*, 6, 24, 224–225
 - Cyclooxygenase (COX)-1, 191
 - Cyclooxygenase (COX)-1 inhibitors, 194
 - Cystic fibrosis
 - chronic rhinosinusitis associated with, 8, 10, 75, 96, 168–170
 - cilia abnormalities associated with, 207
 - diagnosis of, 216
 - genetic testing for, 209
 - impaired mucociliary clearance associated with, 8, 32
 - nasal polyps associated with, 10, 168, 169, 209
 - sinonasal symptoms of, 46
 - Cystic Fibrosis Foundation, 169
 - Cystic fibrosis gene mutations, 168–169, 209
 - Cysts, intramucosal, 59, 98–99
 - Cytokines, 24, 31, 109, 112
 - Cytology, nasal, 115
- ## D
- Decongestants
 - as acute bacterial rhinosinusitis treatment, 19, 67–68
 - as acute rhinosinusitis treatment, 123–124
 - adverse effects of, 55, 68
 - as allergic rhinitis treatment, 122, 123–124
 - as chronic rhinosinusitis treatment, 21, 87
 - contraindication as chronic rhinosinusitis treatment, 124
 - herbal, 136
 - as Samter’s triad treatment, 196
 - side effects of, 124
 - as subacute rhinosinusitis treatment, 19
 - use in children, 215
 - use in nasal endoscopic examinations, 56

“Dennie’s lines,” 113
 Dental examinations, for halitosis
 evaluation, 53
 Dental pathology, as rhinosinusitis cause, 51,
 54, 65–66, 209
 Desensitization
 to aspirin, 196–197, 200
 to fungal antigens, 6
 Desloratadine, 122–123
 Dexamethasone, contraindication in pediatric
 patients, 215
 Diabetic patients, fungal rhinosinusitis in, 5,
 230–231, 232–233
 Diathermy, submucosal, 256–257
 Diphenhydramine, 122
 Dust mites, 6–7, 208
 Dyskinesia, ciliary, 8, 32, 75, 96, 207, 217
 Dysplasia, fibrous, 158–159

E

Ecballium elaterium, 134, 136
Echinacea, 134–135, 136
 Echinocandins, 174
 Edema, mucosal
 allergic rhinitis-related, 113
 in children, 207
 chronic rhinosinusitis-related, 47, 56–57
 imaging studies of, 34, 35
 Empyema, subdural, 37, 152–153
 Encephaloceles, 149, 156, 157
 Endoscopic middle meatal cultures
 (EMMC), 33
 Endoscopic sinus surgery, *see* Functional
 endoscopic sinus surgery (FESS)
 Endoscopy
 esophageal, 53
 nasal, diagnostic, 2, 56–58, 94
 of acute rhinosinusitis, 32–33, 38
 of allergic rhinitis, 114
 of chronic rhinosinusitis, 56–58
 postoperative, 98
 preoperative, 98, 253
 Enterovirus, 30
 Environmental control, of allergens, 120–121
 Environmental factors, in rhinosinusitis, 4–8,
 55, 96
 in children, 208–209
 implication for functional endoscopic sinus
 surgery (FESS), 96
 Eosinophils, 109, 112, 115, 119
 Epistaxis
 cocaine abuse-related, 182–183
 evaluation of, 54

 hereditary hemorrhagic telangiectasia-
 related, 180–181
 Wegener’s granulomatosis-related, 165
 Erythema, chronic rhinosinusitis-related,
 56–57
 Erythrocyte sedimentation rate (ESR), 33
 Erythromycin, 67
 bacterial resistance to, 5
 Esberitox, 134, 136
Escherichia coli, as chronic pediatric
 rhinosinusitis cause, 213
 Esthesioneuroblastomas, 158, 159, 162
 Estrogen, 10
 Ethmoid air cells, 146, 147
*European Position Paper on Rhinosinusitis and
 Nasal Polyps* (European Academy
 of Allergology and Immunology),
 2, 32, 46, 60

F

Facial congestion, rhinosinusitis-related, 12
 Facial pain
 acute bacterial rhinosinusitis-related,
 209–210
 chronic rhinosinusitis-related, 43, 51
 differential diagnosis of, 51
 objective evaluation of, 51
 as rhinosinusitis diagnostic criteria, 2, 30,
 31, 32
 Facial vein, 148
 Family history, of chronic rhinosinusitis, 55, 56
 Fatigue, 12, 172
 Fever, 29–30, 31, 37, 209–210
 Fexofenadine, 122–123
 Fibromas, 158–159
 Fistulas, oronasal, 177
 Flunisolide, 125, 189, 215–216
 Fluoroquinolones, 215
 bacterial resistance to, 5
 Fluticasone furoate, 125
 Fluticasone propionate, 125–126, 215
 Foreign bodies, nasal, 19, 32, 208
 Functional endoscopic sinus surgery (FESS),
 93–106
 as augmentation to medical therapy, 95
 balloon sinuplasty in, 258–259
 in children, 216
 for chronic rhinosinusitis
 with comorbid allergic fungal
 sinusitis, 86
 imaging studies following, 151–152
 imaging studies prior to, 151
 comparison with adenoidectomy, 261

- complications of, 101, 104–105
 - computed tomographic evaluation of, 151–152
 - failure of, 96
 - goals of, 258
 - imaging modalities for, 148–149, 151–152
 - nasal irrigation following, 79, 80
 - patient preparation for, 100–101
 - postoperative management, 103–104
 - procedure, 101–103
 - revision interventions following, 96
 - as Samter's triad treatment, 197–200
 - selection of patients for, 96–100
 - selection of surgeons for, 100
 - success rates, 198
- Fungal antigens, desensitization to, 6
- Fungal balls (mycetoma), 22, 23, 46, 172, 173
 - in children, 217
 - diagnosis of, 98
 - as headache cause, 226
 - in immunocompromised patients, 224
 - treatment of, 24
- Fungal rhinosinusitis/sinusitis, 5, 22–24, 172–174, 223–236
 - allergic, 22, 24, 75, 172, 173, 225–230
 - causal organisms of, 24
 - definition of, 224
 - diagnosis of, 24, 225–228
 - noninvasive, 224–230
 - treatment of, 24, 99–100, 127, 228–230
 - in children, 217
 - chronic rhinosinusitis, 6, 80–81, 96, 172–175, 179
 - in immunocompromised patients, 10
 - imaging of, 85, 161
 - invasive (fulminant or chronic), 152–153, 172–173, 230–236
 - acute, 22, 23, 230–235
 - chronic, 22, 23–24, 235–236
 - diagnosis of, 231–232, 235
 - treatment of, 232–236
 - nonallergic eosinophilic, 227
 - noninvasive, 172, 173, 224–230
 - allergic, 224–229
 - causal organisms of, 223–225
 - presenting as fungal balls, 22, 23, 24, 46, 98, 172, 173, 217, 224, 225
 - saprophytic, 22, 24
 - treatment of, 84, 85, 86, 99–100, 175
- Fungi
 - environmental exposure to, 55
 - See also names of specific fungi*
 - Fusarium*, 225
- G**
- Gatifloxacin, 215
- Garlic, 136
- Gastroesophageal reflux disease (GERD), 53, 209, 217
- Genetic disorders, as rhinosinusitis risk factor, 10
- Genetic factors, in chronic rhinosinusitis, 55, 56
- Gentamycin, 79
- Ginger, 136
- Ginko, 136
- Granulomatous disorders, 46, 96
 - Churg–Strauss syndrome, 169
 - invasive fungal sinusitis, 234
 - lethal midline granulomas, 183
 - rhinoscleroma, 176
 - sarcoidosis, 167, 168
 - Wegener's granulomatosis, 32, 165–167, 177
- H**
- Haemophilus influenzae*
 - as acute rhinosinusitis cause, 4–5, 30, 31, 70, 76
 - antibiotic resistance in, 5, 212
 - as chronic rhinosinusitis cause, 6, 212–213
 - as pediatric rhinosinusitis cause, 212–213
- Haemophilus influenzae* vaccine, 212, 216–217
- Halitosis, 53, 54, 210
- Haller cells, 146
- Hay fever, 138
- Headaches, rhinosinusitis-related
 - acute rhinosinusitis-related, 31, 37
 - chronic rhinosinusitis-related, 42, 51
 - differential diagnosis of, 51
 - effect on quality of life, 251
 - fungal balls-related, 225
 - isolated sphenoid sinusitis-related, 220
 - migraine, 97
 - objective evaluation of, 51
 - prevalence of, 12
- Health care costs, rhinosinusitis-related, 11–12, 31, 251
- Helicobacter pylori*, 10
- Hematoma
 - orbital, 152
 - saprophytic fungal growth on, 24
- Hemorrhage, intraoperative, 100–101

- Herbal medicines, 133, 134–136, 137
- Histamine, 30, 111, 115
- Homeopathy, 133, 137–138
- Hormonal factors, in rhinosinusitis, 10, 55
- House dust mites, 6–7, 208
- Human immunodeficiency virus (HIV)
infection
in children, 217
definition of, 181
diagnosis of, 181–182
invasive fungal sinusitis associated
with, 230
management of, 181
mycobacterial infections associated
with, 175
as rhinosinusitis risk factor, 9–10, 181–182
- Human placental growth hormone, 10
- Humming, 140
- Hydroxyzine, 122
- Hyperemia, 32, 113–114
- Hypersensitivity reactions, definition of, 110
- Hyphae, fungal, 23
- Hyposmia, rhinosinusitis-related, 97
- I**
- Ibuprofen, preoperative termination of,
100–101
- Imaging, diagnostic, 145–162
preoperative, 254
of specific disease processes
acute rhinosinusitis, 34–37
congenital lesions, 156, 157
inflammatory disease/rhinosinusitis,
150–156
neoplasms, 156, 158–162
See also Computed tomography; Magnetic
resonance imaging; X-rays
- Immune system, humoral and cellular
mediators of, 109
- Immunity
adaptive, 25–26
definition of, 109
innate, 25
- Immunocompromised patients
fungal balls in, 24, 225
fungal rhinosinusitis in, 5, 6, 10, 22, 23,
99–100, 172, 173, 225, 231
pediatric
fungal infections in, 217
rhinosinusitis in, 210
sinusitis in, 230–231
See also Acquired immunodeficiency
syndrome (AIDS); Human
immunodeficiency virus (HIV)
infection
- Immunodeficiencies
as chronic rhinosinusitis risk factor, 55, 75
common variable, 6, 9, 55
as rhinosinusitis risk factor, 9–10, 96
See also Acquired immunodeficiency
syndrome (AIDS); Human
immunodeficiency virus (HIV)
infection
- Immunoglobulin(s), 109
- Immunoglobulin A
deficiency of, 216–217
secretory, 24, 55
- Immunoglobulin E
in allergic fungal sinusitis, 225–226, 227
in allergic response, 110
in allergic rhinitis, 118, 119
in allergy testing, 115–116, 117–118
in immune response, 190
total, 115
- Immunological testing, 9, 216–217
- Immunology, of rhinosinusitis, 24–26, 30–31
- Immunosuppressive therapy, for
mucormycosis, 231–232
- Immunotherapy
for allergic fungal sinusitis, 225
for allergic rhinitis, 126–127, 190
for chronic rhinosinusitis, 81–89
- Infections
imaging of, 149
peri-orbital, 152–153
- Infectious diseases, as chronic rhinosinusitis
cause, 172–177
fungal infections, 6, 10, 80–81, 96,
172–174, 177
mycobacterial infections, 175
rhinoscleroma, 176–177
syphilis, 174–175, 177
- Inflammation
measurement of, 60
post-functional endoscopic sinus surgery,
103, 105
preoperative control of, 100
role in nasal polyp etiology, 187
serologic markers for, 33
- Inflammatory disease, differentiated from
tumors, 161
- Influenza, 66, 137
- Influenza A virus, 30
- Influenza B virus, 30
- Infundibulum/ostio-meatal complex, atelectatic,
151, 152

- Intradermal dilutional testing (IDT), 117
 Intradermal (ID) testing, 116–117
 Ipratropium, 68, 69
Isodon japonicus, 136
 Itraconazole, 229, 234, 235
 fungal resistance to, 174
- K**
 Kartagener's syndrome, 8
 Ketolide antibiotics, 71
Klebsiella pneumoniae, 212–213
Klebsiella rhinoscleromatis, 176, 177
- L**
 Lactoferrin, 25
 Laryngopharyngeal reflux, 10, 44, 50
 Lasers, contraindication in endoscopic sinus surgery, 102
 Laser therapy, for turbinate reduction, 257
 Leukocyte proteinase inhibitor, secretory, 25
 Leukotriene inhibitors, *see* Antileukotriene therapy
 Leukotrienes, 111
 definition of, 126
 in Samter's triad, 190–193, 194
 Levocetirizine, 122–123
 Levofloxacin, 77, 215
 Loratadine, 122–123
 Lupus, 171–172
 Lymphoid tumors, 177
 Lymphoma, 162
 Lysozymes, 25
- M**
 Macrolide antibiotics, 71, 88
 streptococcal resistance to, 31
 use in children, 213–214
 Magnetic resonance imaging, 149
 of acute rhinosinusitis, 34, 35
 of allergic fungal sinusitis, 98
 of congenital lesions, 156, 157
 of fungal sinusitis, 173, 174, 230
 of inflammatory disease/rhinosinusitis, 153, 155–156
 of neoplasms, 156, 158–162
 of pediatric rhinosinusitis, 210, 211
 preoperative, 253
 Mast cells, 109
 Maxillary artery, 148
 Maxillary vein, 148
 Maxillectomy, as mucormycosis treatment, 233, 234
 Melanoma, 162, 178
 Meningitis, 152–153, 217, 219, 220, 242, 244
 Meningo(encephalo)celes, 156, 157
 Metastatic cancer, of the nasal cavity, 177
 Methicillin resistance, in *Staphylococcus aureus*, 80
 Microbiology, of rhinosinusitis, 17–24
 of acute bacterial rhinosinusitis, 18–20, 30
 of acute rhinosinusitis, 4–5
 of chronic rhinosinusitis, 6, 20–21, 76, 78–79
 in children, 212–213
 See also names of specific bacteria and fungi
 Midface anatomic anomalies, as rhinosinusitis risk factor, 209
 Mikulicz cells, 177
 Mind-body medicine, 133–134
 Modified quantitative testing (MQT), 117
 Molds
 allergies to, 208
 as noninvasive sinusitis cause, 223–225
 Mometasone, 125
 Mometasone furoate, 215–216
 Montelukast (Singulair), 126, 194, 195, 197
Moraxella catarrhalis
 as acute rhinosinusitis cause, 4–5, 26, 70, 76
 antibiotic resistance in, 5, 212
 as chronic rhinosinusitis cause, 6, 212–213
 as pediatric rhinosinusitis cause, 212–213
 Moxifloxacin, 215
 Mucocoeles, 97, 99, 154–156, 217
 Mucociliary clearance, 17, 148, 147
 evaluation of, 60
 function of, 25
 impaired, 25
 allergic rhinitis-related, 32
 cystic fibrosis-related, 8, 32
 viral infection-related, 18, 66
 microscopic and endoscopic visualization of, 94
 Mucociliary transport time (CT), 60
 Mucoepidermoid carcinoma, 162
 Mucolytics, 69, 72, 87
 Mucopycoceles, 155
 Mucormycosis, 6, 23, 230, 232–233
 Mucosa
 in allergic rhinitis, 113
 “cobblestoning” of, 114
 edematous
 allergic rhinitis-related, 113
 in children, 207
 chronic rhinosinusitis-related, 47, 56–57

- Mucosa (*cont.*)
- imaging studies of, 34, 35
 - inflamed, 47
 - innervation of, 252
 - minor thickening of, 59
 - in nonallergic rhinitis, 113–114
- Mucous blanket, sinonasal, 25
- Mucous transport therapy, 69, 72
- Mupirocin, 80
- Mycetoma, *see* Fungal balls (mycetoma)
- Mycobacterial infections, 175, 176
- Myrtol, 136
- N**
- Nasal cavity
- anatomy of, 94, 145–148
 - endoscopic visualization of, 94
 - imaging of, 150
- Nasal cavity swabs, 33
- Nasal congestion
- acute rhinosinusitis-related, 32
 - allergic rhinitis-related, 112
 - effect on quality of life, 251
 - nonspecific, in children, 208
 - rhinosinusitis-related, 12, 97
 - treatment of, *see* Decongestants
 - unilateral, 97
- Nasal discharge
- acute rhinosinusitis-related, 22, 32
 - bacterial rhinosinusitis-related, 209–210
 - chronic rhinosinusitis-related, 43, 50, 56, 57
 - differential diagnosis of, 50
 - imaging of, 149, 161
 - objective evaluation of, 50
 - as rhinosinusitis diagnostic criteria, 2
 - rhinosinusitis-related, 97
 - viral rhinosinusitis-related, 209
 - See also* Postnasal drip; Rhinorrhea
- Nasal irrigation, 139
- as antibiotic delivery method, 79–80, 81
 - saline
 - as acute bacterial rhinosinusitis therapy, 69
 - as allergic rhinitis treatment, 139–140
 - use in children, 215
 - as saprophytic fungal rhinosinusitis prophylaxis, 24
- Nasal obstruction
- acute rhinosinusitis-related, 31
 - chronic rhinosinusitis-related, 43, 47–48
 - decongestants-related, 55
 - differential diagnosis of, 48
 - objective evaluation of, 48–49
 - pregnancy-related, 55
 - tumor-related, 48, 49, 97
 - unilateral, 97
- Nasal peak inspiratory flow (NPIF), 49
- Nasal secretions
- aspiration of, 189
 - See also* Nasal discharge
- Nasal septum
- anatomy of, 146, 252
 - deformities or deviations of, 58, 252
 - as nasal obstruction cause, 48, 252
 - as rhinosinusitis cause, 8–9, 96
 - surgical repair of, 254–255
 - endoscopic visualization of, 94, 95
- Nasal sprays
- steroid, 21, 66–67, 81–84, 215–216
 - zinc-containing, 55
- Nasal valve
- collapse repair of, 254
 - dysfunction of, 48
- Nasal vestibule, bacterial colonization of, 17
- Nasofrontal duct, 146
- Nasolacrimal duct, 147
- Nasopharyngeal carcinoma, 208
- Nasopharynx
- anatomy of, 252
 - bacterial colonization of, 17
- Nasotracheal/nasogastric intubation, as pediatric sinusitis risk factor, 209
- National Health Interview Study, 31
- National Institutes of Health, National Center for Complementary and Alternative Medicine, 133
- Natural killer cells, 109
- Nitric oxide, 140
- Nitric oxide metabolites, 136
- Nonsteroidal anti-inflammatory drugs
- contraindication in Samter’s triad patients, 194
 - preoperative termination of, 100–101
 - See also* Aspirin
- Nose
- anatomic anomalies of, 209
 - anatomy and physiology of, 252
 - See also* Nasal cavity
- Nosebleeds, *see* Epistaxis
- Nuclear scintigraphy, 156
- O**
- Occupational factors, in rhinosinusitis, 55
- “One Airway Hypothesis,” 188–190

- Ophthalmic artery, 147–148
- Ophthalmic veins, 147–148
- Orbit
- functional endoscopic sinus surgery (FESS)-related injury to, 152
 - involvement in acute rhinosinusitis, 37
 - involvement in rhinosinusitis, 241–244
 - in children, 218–220
 - tumor metastases into, 158, 161
- Orbital exenteration, as mucormycosis treatment, 232–233
- Organ transplant recipients, fungal rhinosinusitis in, 23, 172
- Osteitis, 20, 37
- Osteomas, 158–159
- Osteomyelitis, 37, 78, 217
- Ostiomeatal complex
- anatomy of, 146, 147
 - computed tomography of, 98
 - obstruction of, 6, 9, 18, 146, 216
 - persistent inflammation of, 96
 - role in sinus drainage, 146, 147
- Otitis media, 10, 19, 210, 212, 216, 217, 251
- Otoscopes, 114
- Oxymetazole (Afrin[®]), 55, 68, 124, 136, 215
 - use in nasal endoscopic examinations, 56
- P**
- Pain assessment scales, 51
- Papillomas, 58, 159, 160
- Parainfluenza virus, 30–31
- Penicillin
- bacterial resistance to, 5, 212, 215
 - as syphilis treatment, 175
- Penicillin allergy, 71, 175
- Penicillium*, 225
- Pharyngeal pouch, 53
- Phenylephrine, 124
- Phenylephrine hydrochloride, 215
- Phenylpropanolamine, 67–68
- Phototherapy, 140, 257–258
- Pneumococcal vaccine, 212
- Pneumonia, 98
- Pollen, as allergic rhinitis trigger, 120
- Pollution, as rhinosinusitis risk factor, 4, 8, 96
- Polychondritis, relapsing, 171
- Polyps, nasal, 96
 - allergic fungal sinusitis-related, 225–226
 - asymptomatic, 98
 - in children, 209
 - chronic rhinosinusitis-related, 44–45, 56, 114
 - cystic fibrosis-related, 10, 168–169, 209
 - definition of, 98
 - etiology of, 187
 - histologic examination of, 178
 - intramucosal cyst-related, 98–99
 - as nasal obstruction cause, 47
 - pathophysiology of, 44–45
 - regression of, 98
 - treatment of
 - intranasal steroid injection therapy, 83–84
 - office treatment, 259–260
 - in Samter's triad patients, 197, 199–200
 - topical intranasal corticosteroids, 125–126
- Posaconazole, 234, 235, 236
- Postnasal drip, 189
 - allergic rhinitis-related, 112
 - as cough cause, 52
 - effect on quality of life, 251
 - post-Vidian neurectomy, 261
- Pott, Percival, 246
- “Pott's puffy tumor,” 217, 243, 246–248
- Pregnancy, sinonasal symptoms of, 10–11, 55
- Preventive Allergy Treatment (PAT) study, 190
- Prick testing, 116–117
- Progesterone, 10
- Prostaglandin E₂, in Samter's triad, 191–193
- Pseudoallescheria*, 225
- Pseudoallescheria bipolaris*, 23–24
- Pseudoallescheria boydii*, 6, 23–24
- Pseudomonas*, antibiotic therapy for, 80
- Pseudomonas aeruginosa*, 169
 - as acute rhinosinusitis cause, 5, 76
 - in AIDS patients, 10
 - biofilms of, 21
 - as chronic rhinosinusitis cause, 78
 - in children, 213
 - as subacute rhinosinusitis cause, 20
- Pulmonary function tests, 53
- Q**
- Quality of life, factors affecting
 - acupuncture, 137
 - allergy, 118–119
 - chronic rhinosinusitis, 41
 - facial pain, 51
 - rhinosinusitis, 12, 17, 251
 - septoplasty, 254–255
- Quinolones, 71, 77
- R**
- Radiology, diagnostic, *see* Imaging, diagnostic
- Rapid plasma reagin (RPR) test, 175

- Ravuconazole, 236
- Reactive airways disease
unified airway hypothesis of, 188–190
See also Allergic rhinitis; Asthma
- Renal cell carcinoma, metastatic, 162
- Reidu–Osler–Weber syndrome, 179–181
- Respiratory syncytial virus, 30–31
- Reticular tumors, of the nasal cavity, 178
- Rhinitis
atopic, 255
definition of, 111
inflammation associated with, 111
vasoactive, treatment of, 261–262
See also Allergic rhinitis
- Rhinitis medicamentosa, 17, 48, 55, 87
- Rhinometry, nasal, 49
- Rhinorrhea
effect on quality of life, 251
purulent
acute rhinosinusitis-related, 31, 32, 114
chronic rhinosinusitis-related, 114
pediatric acute rhinosinusitis-related, 210
- Rhinoscleroma, 176–177
- Rhinoscopy, anterior, 32, 58
- Rhinosinusitis
as asthma risk factor, 188
bacterial, 207
See also Acute bacterial rhinosinusitis;
Chronic rhinosinusitis
classification of, 1, 3
complications of, 239–248
in adolescents, 37, 205, 239
in children, 205, 217–220, 239
distant, 239, 240
intracranial, 244–246
local, 239, 240
orbital, 241–244
definition of, 1–3, 45, 207, 239, 251
standardized, 12
diagnosis of, 1–2, 252–253
computed tomography-based, 1–2
diagnostic criteria, 2, 29–30
immunological testing in, 9
economic cost of, 11–12, 31, 251
effect on quality of life, 12, 17, 251–252
eosinophilic mucin-type, 226
epidemiology of, 4
etiologic factors in, 4–11
anatomic factors, 4, 8–9
environmental factors, 4–8
systemic diseases, 4
frontal, imaging studies of, 34
location of, 150
maxillary, imaging studies of, 34, 35
occupational, 55
pathophysiology of, 17
prevalence and incidence of, 12, 17, 31, 252
recurrent, 207
in children, 208
refractory, 9
relationship with allergic rhinitis, 118–119
signs and symptoms of, 1, 2, 3
vascular spread of, 240
- Rhinosinusitis Disability Index (RSDI), 139
- Rhinosinusitis Task Force, 29
- Rhinostrometry, 49
- Rhinovirus, 18, 30
Rhizopus, 23
- Russell bodies, 177
- S**
- Saddle nose deformity, 166, 182
- St. John's wort, 136
- Saline irrigation/nasal spray
as acute bacterial rhinosinusitis
treatment, 69
as allergic rhinitis treatment, 139
use in children, 215
- Salivary gland tumors, 162
- Samter, Max, 190
- Samter's triad, 187–188, 190–200
assessment and diagnosis of, 193
asthma associated with, 187
differentiated from aspirin allergy, 191
epidemiology of, 190
nasal polyps associated with, 187
pathophysiology of, 187, 191–193
treatment of, 187
aspirin desensitization, 196–197, 200
medical therapy, 194–196
surgical management, 197–200
- Sarcoidosis, 32, 167–168
- Sarcoma, 162, 177
- Septoplasty, 254–255
- Septum, *see* Nasal septum
- Serial endpoint titration (SET), 117
- Serratia marascens*, 10
- Shea butter, 134
- Sinonasal cavity
blood supply to, 147–148
See also Nasal cavity; Sinuses, paranasal
- Sino-nasal Outcome Test (SNOT-20), 12
- Sinuplasty, balloon, 102
- Sinupret[®], 134, 135

- Sinus disease
- ethmoidal, 9
 - maxillary, 9
 - See also* Rhinosinusitis; Sinusitis
- Sinuses, paranasal
- anatomy of, 205, 206, 239–240
 - aspiration of bacteria into, 207
 - blood supply to, 147–148
 - development of, 205, 206–207
 - drainage patterns in, 145–146, 206–207
 - ethmoid
 - computed tomography of, 93
 - development of, 145, 205, 206–207
 - functional endoscopic sinus surgery of, 101–102
 - mucocoeles of, 99
 - frontal
 - computed tomography of, 98
 - development of, 145, 205, 206–207
 - functional endoscopic sinus surgery of, 101–102
 - nasal endoscopy of, 98
 - maxillary
 - computed tomography of, 98
 - development of, 145, 205, 206
 - functional endoscopic sinus surgery of, 101–102
 - mucocoeles of, 99
 - nasal endoscopy of, 98
 - physiology of, 206–207
 - sphenoid
 - computed tomography of, 98
 - development of, 145, 205, 206–207
 - fungal balls within, 173
 - mucocoeles of, 99
 - nasal endoscopy of, 98
 - spread of rhinosinusitis through, 239–240
 - venous drainage of, 148
- Sinusitis
- ethmoid
 - in children, 244
 - with subperiosteal abscess, 243
 - surgical treatment of, 93
 - symptoms of, 97
 - underdiagnosis of, 59
 - frontal
 - epidural abscess associated with, 245–246
 - intracranial complications of, 219, 220
 - as “Potts puffy tumor” cause, 217, 243, 246–248
 - symptoms of, 97
 - maxillary
 - microbiology of, 18
 - of odontogenic origin, 18, 19
 - overdiagnosis of, 59
 - surgical treatment of, 93
 - symptoms of, 97
 - sphenoid
 - isolated, 220
 - microbiology of, 18
 - unilateral, 19
 - See also* Rhinosinusitis
- Sinus surgery
- antrostomy, 148
 - in children, 207
 - open approaches in, 93, 94–95, 102–103
 - See also* Functional endoscopic sinus surgery (FESS); Surgical treatment, of rhinosinusitis
- Skin testing, 114, 115–117
- Skull base tumors, 99
- Smell, sense of, reduction or loss of, *see* Anosmia
- Smoking
- post-functional endoscopic sinus surgery (FESS), 96
 - as rhinosinusitis risk factor, 8, 55, 96
- Social history, of chronic rhinosinusitis, 55
- Sphenopalatine artery, 148
- Sporothrix schenckii*, 6, 23–24
- Squamous cell carcinoma, 159, 162, 177
- Staphylococcus*
- as chronic rhinosinusitis cause, in cocaine abusers, 182
 - coagulase-negative, as chronic rhinosinusitis cause, 6, 20
 - as intracranial abscess cause, 245
 - as orbital infection cause, 241, 242
- Staphylococcus aureus*
- as acute rhinosinusitis cause, 5, 26, 76
 - biofilms of, 21
 - as chronic rhinosinusitis cause, 6, 20, 21, 70, 78
 - methicillin-resistant, 80
 - in nasal vestibule, 17
 - as orbital infection/abscess cause, 219
 - as pediatric rhinosinusitis cause, 212–213
 - as subacute rhinosinusitis cause, 20
 - treatment of, 215
- Staphylococcus epidermidis*, in nasal vestibule, 17
- Steroid therapy, *see* Corticosteroid therapy

- Streptococcus*
 as chronic rhinosinusitis cause, in cocaine abusers, 183
 group A, macrolide-resistant, 31
 as orbital infection cause, 241, 242
- Streptococcus pneumoniae*
 as acute rhinosinusitis cause, 4–5, 29, 30, 70
 antibiotic resistance in, 71, 213–215
 multidrug-resistance, 214
 as chronic rhinosinusitis cause, 6
 in children, 212–213
 as intracranial abscess cause, 245
 as meningitis cause, 245
 as orbital infection/abscess cause, 219
 as pediatric rhinosinusitis cause, 212
 penicillin resistance in, 5, 212, 215
- Streptococcus pyogenes*, as acute rhinosinusitis cause, 5
- Subacute rhinosinusitis, 20, 207
 definition of, 29–30
 symptoms of, 29–30
- Surgical treatment, of rhinosinusitis
 adjunctive surgical procedures, 251–262
 adenoidectomy, 260–261
 anatomic and physiological considerations in, 252
 balloon sinuplasty, 258–259
 nasal septal deviation resection, 254–255
 nasal valve collapse repair, 254–255
 preoperative considerations in, 252–253
 sinonasal polyp treatment, 259–260
 turbinate surgery, 255–257
 ultraviolet phototherapy, 257–258
 Vidian neurectomy, 261–262
See also Functional endoscopic sinus surgery (FESS)
- Sweat chloride test, 46, 169, 216–217
- Swimming, as bacterial rhinosinusitis risk factor, 209
- Syphilis, 174–175, 177
- Systemic diseases, as chronic rhinosinusitis cause, 165–186
 autoimmune disorders, 165–172
 Churg–Strauss syndrome, 169–170
 cystic fibrosis, 168–169
 lupus, 171–172
 relapsing polychondritis, 171
 sarcoidosis, 167–168
 Wegener's granulomatosis, 165–167, 177
 hematologic–oncologic illnesses, 177–182
 hereditary hemorrhagic telangiectasia, 179–181
 human immunodeficiency virus infection, 181–182
 neoplasms, 177–179
 infectious diseases, 172–177
 fungal infections, 6, 10, 80–81, 96, 172–174
 mycobacterial infections, 175–176
 rhinoscleroma, 175–176
 syphilis, 174–175, 177
- Systemic lupus erythematosus, 171–172
- T**
- Telangiectasia, hereditary hemorrhagic, 179–181
- Terfenadine, 122–123
- Thrombophlebitis, 37, 152–153
- Thrombosis
 cavernous sinus, 152–153, 219, 241, 244, 246
 sagittal sinus, 246
 venous sinus, 246
- T lymphocytes, 109
 in allergic response, 110
- Tobacco smoke, as allergic rhinitis trigger, 120
- Tobramycin, 79
- Transitional cell carcinoma, 178
- Treacher Collins' syndrome, 209
- Triamcinolone, 83–84, 215
- Triamcinolone acetonide, 125
- Triazoles, 174
- Trimethoprim/sulfamethoxazole, use in children, 213
- Tumors, nasal, 99, 100
 benign, 58, 158–159, 160
 as chronic rhinosinusitis cause, 177–179
 as chronic rhinosinusitis mimic, 54
 imaging of, 149, 156, 158–162
 malignant, 158, 159–162
 as nasal obstruction cause, 48, 49, 97
- Turbinates
 embryonic development of, 205
 hypertrophy of, 48, 207
 inferior, 146
 in allergic rhinitis, 113
 endoscopic visualization of, 94
 surgical resection of, 255–257
 middle
 aerated (concha bullosa), 9, 96, 146, 207
 endoscopic visualization of, 94, 95

- superior, 146
- supreme, 146
- Turbinoplasty, radiofrequency, 257
- U**
- Ultrasound, for acute rhinosinusitis diagnosis, 34
- Ultraviolet phototherapy, 257–258
- Uncinate process, 146, 147
 - anatomic variants of, 151, 152
- University of Pennsylvania Smell Identification Test (UPSIT), 52
- Upper esophageal sphincter, incompetence of, 53
- Upper respiratory tract infections
 - involvement of sinuses in, 97–98
 - viral
 - as acute bacterial rhinosinusitis risk factor, 17, 18, 30–31, 66, 69
 - as bacterial rhinosinusitis risk factor, 208
 - as pediatric sinusitis risk factor, 207
- Urtica dioica*, 139
- V**
- Valerian, 136
- Venereal Disease Research Laboratory (VDRL) test, 175
- Vidian nerve, 252
- Vidian neurectomy, 261–262
- Viral rhinosinusitis, 4–5, 18
 - complementary and alternative therapy for, 133–134, 139
 - definition of, 29–30
 - differentiated from acute bacterial rhinosinusitis, 32
 - imaging studies of, 34
 - progression to bacterial rhinosinusitis, 207–208
 - symptoms of, 209–210
- Visual impairment, 243
- Vitamin C (ascorbic acid), 139
- Vitamin E, preoperative termination of, 100–101
- Voriconazole, 174, 234–235, 236
- W**
- Wegener's granulomatosis, 32, 165–167, 177
- Wheal and flare reaction, 115–116
- Work absenteeism, rhinosinusitis-related, 12, 251
- Work environment, as rhinosinusitis risk factor, 55
- X**
- X-rays, 148
 - of chronic rhinosinusitis, 59
 - contraindication in chronic rhinosinusitis evaluation, 59
 - of pediatric rhinosinusitis, 210–211
- Y**
- Yeasts, as noninvasive sinusitis cause, 223–225
- Z**
- Zafirlukast (Accolate), 126, 194, 195
- Zileuton (Zyflo), 126, 194, 195
- Zygomycosis, 230, 233